Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2023 | Assessing chemotherapy and immunotherapy in dMMR endometrial cancer

Domenica Lorusso • 23 Oct 2023
ESMO 2023
Endometrial Cancer Gynecological Cancer Carboplatin Paclitaxel

Domenica Lorusso, MD, PhD, Fondazione IRCCS National Cancer Institute of Milan, Milan, Italy, provides updates on Phase III trials evaluating chemotherapy and immunotherapy in patients with mismatch repair deficiency (dMMR) or microsatellite instability-high (MSI-H) recurrent/metastatic endometrial cancer. Addition of immunotherapy to carboplatin and paclitaxel increases progression-free survival in this group of patients. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Domenica Lorusso

0:39
ESMO 2023 highlights: KEYNOTE-A18 and more
Domenica Lorusso • 23 Oct 2023
0:52
The importance of HRD testing in ovarian cancer
Domenica Lorusso • 23 Oct 2023
1:14
KEYNOTE-A18: pembrolizumab with chemoradiotherapy for advanced cervical cancer
Domenica Lorusso • 23 Oct 2023
5:23
Latest developments in immunotherapy for advanced/recurrent endometrial cancer
Domenica Lorusso • 5 Dec 2022

Related Videos

0:39
Early diagnosis of ovarian cancer with Pap smears
Sergio Marchini • 8 Apr 2024
0:46
FRa expression and sequencing ADCs in endometrial cancer
Rebecca Porter • 8 Apr 2024
4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
1:11
Clonal hematopoiesis mutations in ovarian carcinomas
Rebecca Porter • 8 Apr 2024
The content of VJOncology is intended for healthcare professionals